



1646
CLPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. 99-130-H)

In re Application of:

Tallman et al.

Serial No. 10/045,230

Filed: November 9, 2001

For: Methods for Screening GABA-Modulatory
Compounds for Specified Pharmacological
Activities

Before the Examiner:
Brannock, M.

Art Unit: 1646

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

In regard to the above identified application:

1. We are transmitting herewith the attached:


- a. Response to the Restriction Requirement;
- b. Postcard.

2. With respect to additional fees no additional fee is required.

3. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.

4. **CERTIFICATE OF MAILING UNDER 37 CFR § 1.8:** The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 4th day of June, 2004.

By :


Steven J. Sarussi
Reg. No. 32,784



Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,

on June 4, 2004 (Date of Deposit).

6/7/04
Date

[Signature]
Name

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Attorney Docket No.: 99-130-H)

In re Application of:

Tallman et al.

Serial No.: 10/045,230

Filed: November 9, 2001

For: Methods for Screening GABA-
Modulatory Compounds for
Specified Pharmacological
Activities

Before the Examiner:
Brannock, M.

Art Unit: 1646

RESPONSE TO THE RESTRICTION REQUIREMENT
MAILED MAY 4, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Responsive to the Restriction Requirement mailed May 4, 2004, Applicants elect the claims of Group III, i.e., claims 24-35, and 49, which are directed to methods of screening compounds for anxiolytic activity.


Applicants urge the Examiner to contact the Applicants' undersigned representative at (312)913-0001 if the Examiner

believes that this would expedite prosecution of this application.

Respectfully submitted,

Dated: February 25, 2002

By:


Steven J. Sarussi
Reg. No. 32,784

McDonnell Boehnen
Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
(312) 913-0001